10
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Questions on Percutaneous Patent Foramen Ovale Closure for Secondary Stroke Prevention: The Heads of the Lernaean Hydra

      article-commentary
      a , * , b
      Cardiology
      S. Karger AG

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references22

          • Record: found
          • Abstract: found
          • Article: not found

          Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke

          Trials of patent foramen ovale (PFO) closure to prevent recurrent stroke have been inconclusive. We investigated whether patients with cryptogenic stroke and echocardiographic features representing risk of stroke would benefit from PFO closure or anticoagulation, as compared with antiplatelet therapy.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke

            The efficacy of closure of a patent foramen ovale (PFO) in the prevention of recurrent stroke after cryptogenic stroke is uncertain. We investigated the effect of PFO closure combined with antiplatelet therapy versus antiplatelet therapy alone on the risks of recurrent stroke and new brain infarctions.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke

              Whether closure of a patent foramen ovale reduces the risk of recurrence of ischemic stroke in patients who have had a cryptogenic ischemic stroke is unknown.
                Bookmark

                Author and article information

                Journal
                CRD
                Cardiology
                10.1159/issn.0008-6312
                Cardiology
                S. Karger AG
                0008-6312
                1421-9751
                2019
                October 2019
                17 July 2019
                : 144
                : 1-2
                : 50-52
                Affiliations
                [_a] aDivision of Hospital Medicine, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA
                [_b] bDepartment of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA
                Author notes
                *Assist. Prof. Leonidas Palaiodimos, MD, MSc, Division of Hospital Medicine, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, 111 East 210th Street, Bronx, NY 10467 (USA), E-Mail leonidas.palaiodimos@gmail.com
                Author information
                https://orcid.org/0000-0003-4682-5991
                Article
                501231 Cardiology 2019;144:50–52
                10.1159/000501231
                31315106
                0341743c-82a9-441b-9c37-fe080a64b41d
                © 2019 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                : 22 May 2019
                : 22 May 2019
                Page count
                Pages: 3
                Categories
                Congenital Heart Disease: Editorial Comment

                General medicine,Neurology,Cardiovascular Medicine,Internal medicine,Nephrology
                General medicine, Neurology, Cardiovascular Medicine, Internal medicine, Nephrology

                Comments

                Comment on this article